Sign inCreate account

Report workspace tools

NCT03005067COMPLETEDanonymous

A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Subjects With Symptoms of Common Cold

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Carbomer 980 (1146A), Placebo

Indication / condition

AI-normalized

Common Cold

Intervention

Source record

Carbomer 980 (1146A), Placebo

Source & freshness

Source record

NCT ID

NCT03005067

Original source

ClinicalTrials.gov

Source last updated

Jun 19, 2018

Ingested at

Jun 08, 2026

Internal sync

Jun 08, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03005067

Title

A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Subjects With Symptoms of Common Cold

Sponsor

GlaxoSmithKline

Status

COMPLETED

Phase

PHASE2

Condition raw

Common Cold

Condition normalized

Common Cold

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Carbomer 980 (1146A), Placebo

Target normalized

Carbomer 980 (1146A), Placebo

Interventions

Carbomer 980 (1146A), Placebo

Public preview

Source record

This study will be conducted in adult participants with symptoms of common cold assessing if 1146A nasal spray reduces the severity of symptoms of the common cold compared to placebo. The study will also evaluate the safety of 1146A compared to placebo.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Subjects With Symptoms of Common Cold

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03005067

Status

COMPLETED

Phase

PHASE2

Sponsor

GlaxoSmithKline

Executive brief

Investment-Ready Snapshot

This study will be conducted in adult participants with symptoms of common cold assessing if 1146A nasal spray reduces the severity of symptoms of the common cold compared to placebo. The study will also evaluate the safety of 1146A compared to placebo.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 19, 2018
Internal syncJun 08, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03005067

Indication

Common Cold

Modality

small molecule

Target

Carbomer 980 (1146A), Placebo

Intervention

Carbomer 980 (1146A), Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.